Novavax (NVAX) is back in the news again, only this time, it’s not because of its COVID-19 vaccine candidate. During the 2020 World Vaccine Congress Washington last week, the vaccine maker presented data from the Phase 3 respiratory syncytial virus (RSV) and NanoFlu programs, with the latter attracting significant attention from the Street.The incremental cell-mediated immunity (CMI) data for NanoFlu, its seasonal quadrivalent influenza vaccine candidate, demonstrated that the asset was able to induce substantially higher polyfunctional CD4+ T cell responses than what had been previously reported for other “enhanced” influenza vaccines in older adults.The Phase 3 NanoFlu program was …read more
Source:: Yahoo Finance
